@article {10757, title = {Antibodies reacting to mimotopes of Simian virus 40 large T antigen, the viral oncoprotein, in sera from children.}, journal = {J Cell Physiol}, volume = {234}, year = {2019}, month = {2019 Apr}, pages = {3170-3179}, abstract = {

Recent data indicate that the Simian virus 40 (SV40) infection appears to be transmitted in humans independently from early SV40-contaminated antipolio vaccines. Serum antibodies against SV40 large T antigen (Tag) were analyzed in children/adolescents and young adults. To investigate antibodies reacting to SV40 Tag antigens, serum samples ( n = 812) from children and young adults were analyzed by indirect ELISAs using specific SV40 Tag mimotopes. Mimotopes were synthetic peptides corresponding to SV40 Tag epitopes. In sera ( n = 412) from healthy children up to 17 years old, IgG antibodies against SV40 Tag mimotopes reached an overall prevalence of 15\%. IgM antibodies against SV40 Tag were detected in sera of children 6-8 months old confirming and extending the knowledge that SV40 seroconversion occurs early in life. In children/adolescents affected by different diseases ( n = 180) SV40 Tag had a prevalence of 18\%, being the difference no significant compared to healthy subjects ( n = 220; 16\%) of the same age. Our immunological data indicate that SV40 circulates in children and young adults, both in healthy conditions and affected by distinct diseases. The IgM detection in sera from healthy children suggests that the SV40 infection/seroconversion occurs early in life (>6 months). Our immunological data support the hypothesis that SV40, or a closely related still unknown polyomavirus, infects humans. The SV40 seroprevalence is lower than common polyomaviruses, such as BKPyV and JCPyV, and other new human polyomaviruses. In addition, our immunological surveillance indicates a lack of association between different diseases, considered herein, and SV40.

}, issn = {1097-4652}, doi = {10.1002/jcp.27490}, author = {Mazzoni, Elisa and Frontini, Francesca and Rotondo, John Charles and Zanotta, Nunzia and Fioravanti, Arianna and Minelli, Francesca and Torreggiani, Elena and Campisciano, Giuseppina and Marcuzzi, Annalisa and Guerra, Giovanni and Tommasini, Alberto and Touz{\'e}, Antoine and Martini, Fernanda and Tognon, Mauro and Comar, Manola} } @article {10849, title = {The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases.}, journal = {Int J Mol Sci}, volume = {19}, year = {2018}, month = {2018 Dec 14}, abstract = {

Lipids and inflammation regulate each other. Early studies on this topic focused on the systemic effects that the acute inflammatory response-and interleukins-had on lipid metabolism. Today, in the era of the obesity epidemic, whose primary complications are cardio-metabolic diseases, attention has moved to the effects that the nutritional environment and lipid derangements have on peripheral tissues, where lipotoxicity leads to organ damage through an imbalance of chronic inflammatory responses. After an overview of the effects that acute inflammation has on the systemic lipid metabolism, this review will describe the lipid-induced immune responses that take place in peripheral tissues and lead to chronic cardio-metabolic diseases. Moreover, the anti-inflammatory effects of lipid lowering drugs, as well as the possibility of using anti-inflammatory agents against cardio-metabolic diseases, will be discussed.

}, keywords = {Anti-Inflammatory Agents, Cardiovascular Diseases, Humans, Hypolipidemic Agents, Immune System, Inflammation, Interleukins, Lipid Metabolism, Lipids, Metabolic Diseases}, issn = {1422-0067}, doi = {10.3390/ijms19124058}, author = {Bernardi, Stella and Marcuzzi, Annalisa and Piscianz, Elisa and Tommasini, Alberto and Fabris, Bruno} } @article {10445, title = {Cytokine profiles of women with vulvodynia: Identification of a panel of pro-inflammatory molecular targets.}, journal = {Eur J Obstet Gynecol Reprod Biol}, volume = {226}, year = {2018}, month = {2018 Jul}, pages = {66-70}, abstract = {

OBJECTIVE: The vulvar pain syndrome (VPS) is a multifactorial disease severely influencing the lifestyle of affected women. Among possible etiological factors, local injury, peripheral and/or central sensitization of the nervous system, and a chronic inflammatory status have been positively associated with the development of VPS. The identification of a constitutive altered local inflammatory profile in VPS women may represent an important point in the characterization of patients{\textquoteright} phenotype as a useful marker influencing the vulvar micro-environment. The aim of this study was to investigative the possible role of the local cytokines production in women with VPS in comparison to healthy women.

STUDY DESIGN: In this study were collected vaginal swabs from 57 healthy women (HC) who never suffered from VPS and from 30 patients diagnosed with vulvodynia (VPS) by at least 3 years and currently symptomatic. All patients included in this study showed the absence of Sexually Transmitted (STD) diseases and Reproductive Tract Infection. Real-time PCR was performed to assess the genomic sequences of ST pathogens. The Luminex Bio-Plex platform was used for the analysis of a panel of 48 immune factors.

RESULTS: Eleven molecules, specifically involved in the pro-inflammatory pathway were significantly modulated in VPS patients in comparison to healthy women, suggesting a persistent inflammatory process.

CONCLUSIONS: Therefore, these inflammatory factors could be possible biological markers involved in this disease. Nevertheless, other studies are needed to consider this specific immune profile as a valid marker of the vulvodynia.

}, keywords = {Adult, Aged, Cytokines, Female, Humans, Inflammation, Middle Aged, Vaginal Smears, Vulva, Vulvodynia, Women{\textquoteright}s Health}, issn = {1872-7654}, doi = {10.1016/j.ejogrb.2018.05.035}, author = {Zanotta, Nunzia and Campisciano, Giuseppina and Scrimin, Federica and Blendi, Ura and Marcuzzi, Annalisa and Vincenti, Ezio and Crovella, Sergio and Comar, Manola} } @article {10440, title = {Neuronal Dysfunction Associated with Cholesterol Deregulation.}, journal = {Int J Mol Sci}, volume = {19}, year = {2018}, month = {2018 May 19}, abstract = {

Cholesterol metabolism is crucial for cells and, in particular, its biosynthesis in the central nervous system occurs in situ, and its deregulation involves morphological changes that cause functional variations and trigger programmed cell death. The pathogenesis of rare diseases, such as Mevalonate Kinase Deficiency or Smith$^{-}$Lemli$^{-}$Opitz Syndrome, arises due to enzymatic defects in the cholesterol metabolic pathways, resulting in a shortage of downstream products. The most severe clinical manifestations of these diseases appear as neurological defects. Expanding the knowledge of this biological mechanism will be useful for identifying potential targets and preventing neuronal damage. Several studies have demonstrated that deregulation of the cholesterol pathway induces mitochondrial dysfunction as the result of respiratory chain damage. We set out to determine whether mitochondrial damage may be prevented by using protective mitochondria-targeted compounds, such as MitoQ, in a neuronal cell line treated with a statin to induce a biochemical block of the cholesterol pathway. Evidence from the literature suggests that mitochondria play a crucial role in the apoptotic mechanism secondary to blocking the cholesterol pathway. Our study shows that MitoQ, administered as a preventive agent, could counteract the cell damage induced by statins in the early stages, but its protective role fades over time.

}, keywords = {Anticholesteremic Agents, Cell Line, Tumor, Cholesterol, Electron Transport, Humans, Lovastatin, Mitochondria, Neurons, Neuroprotective Agents, Organophosphorus Compounds, Ubiquinone}, issn = {1422-0067}, doi = {10.3390/ijms19051523}, author = {Marcuzzi, Annalisa and Loganes, Claudia and Valencic, Erica and Piscianz, Elisa and Monasta, Lorenzo and Bilel, Sabrine and Bortul, Roberta and Celeghini, Claudio and Zweyer, Marina and Tommasini, Alberto} } @article {10843, title = {Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice.}, journal = {Curr Med Chem}, volume = {25}, year = {2018}, month = {2018}, pages = {2783-2796}, abstract = {

BACKGROUND: Mevalonate Kinase Deficiency (MKD, OMIM $\#$610377) is a rare autosomal recessive metabolic and inflammatory disease. In MKD, defective function of the enzyme mevalonate kinase, due to a mutation in the MVK gene, leads to the shortage of mevalonate- derived intermediates, which results in unbalanced prenylation of proteins and altered metabolism of sterols. These defects lead to a complex multisystem inflammatory and metabolic syndrome.

OBJECTIVE: Although biologic therapies aimed at blocking the inflammatory cytokine interleukin- 1 can significantly reduce inflammation, they cannot completely control the clinical symptoms that affect the nervous system. For this reason, MKD can still be considered an orphan drug disease. The availability of MKD models reproducing the MKD-systematic inflammation, is crucial to improve the knowledge on its pathogenesis, which is still unknown. New therapies are also required in order to improve pateints{\textquoteright} conditions and their quality of life.

METHODS: MKD-cellular models can be obtained by biochemical inhibition of mevalonatederived isoprenoids. Of note, these cells present an exaggerated response to inflammatory stimuli that can be reduced by treatment with zaragozic acid, an inhibitor of squalene synthase, thus increasing the availability of isoprenoids intermediates upstream the enzymatic block.

RESULTS: A similar action might be obtained by lapaquistat acetate (TAK-475, Takeda), a drug that underwent extensive clinical trials as a cholesterol lowering agent 10 years ago, with a good safety profile.

CONCLUSIONS: Here we describe the preclinical evidence supporting the possible repositioning of TAK-475 from its originally intended use to the treatment of MKD and discuss its potential to modulate the mevalonate pathway in inflammatory diseases.

}, keywords = {Acyl Coenzyme A, Cholesterol, Drug Repositioning, Farnesyl-Diphosphate Farnesyltransferase, Humans, Hypercholesterolemia, Mevalonate Kinase Deficiency, Oxazepines, Phosphotransferases (Alcohol Group Acceptor), Piperidines}, issn = {1875-533X}, doi = {10.2174/0929867324666170911161417}, author = {Marcuzzi, Annalisa and Loganes, Claudia and Celeghini, Claudio and Kleiner, Giulio} } @article {10518, title = {Curcumin Anti-Apoptotic Action in a Model of Intestinal Epithelial Inflammatory Damage.}, journal = {Nutrients}, volume = {9}, year = {2017}, month = {2017 Jun 06}, abstract = {

The purpose of this study is to determine if a preventive treatment with curcumin can protect intestinal epithelial cells from inflammatory damage induced by IFNγ. To achieve this goal we have used a human intestinal epithelial cell line (HT29) treated with IFNγ to undergo apoptotic changes that can reproduce the damage of intestinal epithelia exposed to inflammatory cytokines. In this model, we measured the effect of curcumin (curcuminoid from ) added as a pre-treatment at different time intervals before stimulation with IFNγ. Curcumin administration to HT29 culture before the inflammatory stimulus IFNγ reduced the cell apoptosis rate. This effect gradually declined with the reduction of the curcumin pre-incubation time. This anti-apoptotic action by curcumin pre-treatment was paralleled by a reduction of secreted IL7 in the HT29 culture media, while there was no relevant change in the other cytokine levels. Even though curcumin pre-administration did not impact the activation of the NF-κB pathway, a slight effect on the phosphorylation of proteins in this inflammatory signaling pathway was observed. In conclusion, curcumin pre-treatment can protect intestinal cells from inflammatory damage. These results can be the basis for studying the preventive role of curcumin in inflammatory bowel diseases.

}, keywords = {Anti-Inflammatory Agents, Non-Steroidal, Apoptosis, Cell Survival, Curcuma, Curcumin, Cytokines, Epithelial Cells, HT29 Cells, Humans, Inflammation, Interferon-gamma, Interleukin-7, Intestinal Mucosa, NF-kappa B, Phosphorylation, Signal Transduction}, issn = {2072-6643}, doi = {10.3390/nu9060578}, author = {Loganes, Claudia and Lega, Sara and Bramuzzo, Matteo and Vecchi Brumatti, Liza and Piscianz, Elisa and Valencic, Erica and Tommasini, Alberto and Marcuzzi, Annalisa} } @article {8323, title = {Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology.}, journal = {Int J Mol Sci}, volume = {17}, year = {2016}, month = {2016}, pages = {365}, abstract = {

Deregulation of the cholesterol pathway is an anomaly observed in human diseases, many of which have in common neurological involvement and unknown pathogenesis. In this study we have used Mevalonate Kinase Deficiency (MKD) as a disease-model in order to investigate the link between the deregulation of the mevalonate pathway and the consequent neurodegeneration. The blocking of the mevalonate pathway in a neuronal cell line (Daoy), using statins or mevalonate, induced an increase in the expression of the inflammasome gene (NLRP3) and programmed cell death related to mitochondrial dysfunction. The morphology of the mitochondria changed, clearly showing the damage induced by oxidative stress and the decreased membrane potential associated with the alterations of the mitochondrial function. The co-administration of geranylgeraniol (GGOH) reduced the inflammatory marker and the damage of the mitochondria, maintaining its shape and components. Our data allow us to speculate about the mechanism by which isoprenoids are able to rescue the inflammatory marker in neuronal cells, independently from the block of the mevalonate pathway, and about the fact that cell death is mitochondria-related.

}, issn = {1422-0067}, doi = {10.3390/ijms17030365}, author = {Marcuzzi, Annalisa and Piscianz, Elisa and Zweyer, Marina and Bortul, Roberta and Loganes, Claudia and Girardelli, Martina and Baj, Gabriele and Monasta, Lorenzo and Celeghini, Claudio} } @article {8315, title = {Putative modifier genes in mevalonate kinase deficiency.}, journal = {Mol Med Rep}, volume = {13}, year = {2016}, month = {2016 Apr}, pages = {3181-9}, abstract = {

Mevalonate kinase deficiency (MKD) is an autosomal recessive auto-inflammatory disease, caused by impairment of the mevalonate pathway. Although the molecular mechanism remains to be elucidated, there is clinical evidence suggesting that other regulatory genes may be involved in determining the phenotype. The identification of novel target genes may explain non-homogeneous genotype-phenotype correlations, and provide evidence in support of the hypothesis that novel regulatory genes predispose or amplify deregulation of the mevalonate pathway in this orphan disease. In the present study, DNA samples were obtained from five patients with MKD, which were then analyzed using whole exome sequencing. A missense variation in the PEX11γ gene was observed in homozygosis in P2, possibly correlating with visual blurring. The UNG rare gene variant was detected in homozygosis in P5, without correlating with a specific clinical phenotype. A number of other variants were found in the five analyzed DNA samples from the MKD patients, however no correlation with the phenotype was established. The results of the presents study suggested that further analysis, using next generation sequencing approaches, is required on a larger sample size of patients with MKD, who share the same MVK mutations and exhibit {\textquoteright}extreme{\textquoteright} clinical phenotypes. As MVK mutations may be associated with MKD, the identification of specific modifier genes may assist in providing an earlier diagnosis.

}, issn = {1791-3004}, doi = {10.3892/mmr.2016.4918}, author = {Marcuzzi, Annalisa and Vozzi, Diego and Girardelli, Martina and Tricarico, Paola Maura and Knowles, Alessandra and Crovella, Sergio and Vuch, Josef and Tommasini, Alberto and Piscianz, Elisa and Bianco, Anna Monica} } @article {7694, title = {Alendronate, a double-edged sword acting in the mevalonate pathway.}, journal = {Mol Med Rep}, volume = {12}, year = {2015}, month = {2015 Sep}, pages = {4238-42}, abstract = {

Aminobisphosphonate aledronate is a compound commonly used clinically for the treatment of osteoporosis and other bone diseases, as a result of it preventing bone resorption. However, in previous years it has also been used to obtain cellular and animal models of a rare genetic disorder termed Mevalonate Kinase Deficiency (MKD). MKD is caused by mutations affecting the mevalonate kinase enzyme, in the cholesterol pathway and alendronate can be used to biochemically mimic the genetic defect as it inhibits farnesyl pyrophosphate synthase in the same pathway. Despite evidence in favor of the inhibition exerted on the mevalonate pathway, there is at least one clinical case of MKD in which alendronate improved not only skeletal and bone fractures, as expected, but also MKD clinical features. Based on this finding, the present study assessed the anti-inflammatory properties of this aminobisphosphonate in vitro. No anti-inflammatory effects of alendronate were observed in the in vitro experiments. Since MKD lacks specific treatments, these results may assist scientists and physicians in making the decision as to the most suitable choice of therapeutic compounds for this neglected disease.

}, issn = {1791-3004}, doi = {10.3892/mmr.2015.3957}, author = {Tricarico, Paola Maura and Girardelli, Martina and Kleiner, Giulio and Knowles, Alessandra and Valencic, Erica and Crovella, Sergio and Marcuzzi, Annalisa} } @article {7787, title = {Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype.}, journal = {Clin Immunol}, volume = {159}, year = {2015}, month = {2015 Jul}, pages = {33-6}, keywords = {B-Lymphocytes, Child, Preschool, Female, Germinal Center, Humans, Hyper-IgM Immunodeficiency Syndrome, Infant, Male, Mutation, Phenotype, Phosphatidylinositol 3-Kinases, RNA Splice Sites, Sequence Analysis, DNA}, issn = {1521-7035}, doi = {10.1016/j.clim.2015.04.014}, author = {Lougaris, Vassilios and Faletra, Flavio and Lanzi, Gaetana and Vozzi, Diego and Marcuzzi, Annalisa and Valencic, Erica and Piscianz, Elisa and Bianco, AnnaMonica and Girardelli, Martina and Baronio, Manuela and Loganes, Claudia and Fasth, Anders and Salvini, Filippo and Trizzino, Antonino and Moratto, Daniele and Facchetti, Fabio and Giliani, Silvia and Plebani, Alessandro and Tommasini, Alberto} } @article {7688, title = {Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency.}, journal = {Apoptosis}, volume = {20}, year = {2015}, month = {2015 Aug}, pages = {1048-55}, abstract = {

Mevalonate kinase deficiency is a rare disease whose worst manifestation, characterised by severe neurologic impairment, is called mevalonic aciduria. The progressive neuronal loss associated to cell death can be studied in vitro with a simplified model based on a biochemical block of the mevalonate pathway and a subsequent inflammatory trigger. The aim of this study was to evaluate the effect of the mevalonate blocking on glial cells (BV-2) and the following effects on neuronal cells (SH-SY5Y) when the two populations were cultured together. To better understand the cross-talk between glial and neuronal cells, as it happens in vivo, BV-2 and SH-SY5Y were co-cultured in different experimental settings (alone, transwell, direct contact); the effect of mevalonate pathway biochemical block by Lovastatin, followed by LPS inflammatory trigger, were evaluated by analysing programmed cell death and mitochondrial membrane potential, cytokines{\textquoteright} release and cells{\textquoteright} morphology modifications. In this experimental condition, glial cells underwent an evident activation, confirmed by elevated pro-inflammatory cytokines release, typical of these disorders, and a modification in morphology. Moreover, the activation induced an increase in apoptosis. When glial cells were co-cultured with neurons, their activation caused an increase of programmed cell death also in neuronal cells, but only if the two populations were cultured in direct contact. Our findings, being aware of the limitations related to the cell models used, represent a preliminary step towards understanding the pathological and neuroinflammatory mechanisms occurring in mevalonate kinase diseases. Contact co-culture between neuronal and microglial cells seems to be a good model to study mevalonic aciduria in vitro, and to contribute to the identification of potential drugs able to block microglial activation for this orphan disease. In fact, in such a pathological condition, we demonstrated that microglial cells are activated and contribute to neuronal cell death. We can thus hypothesise that the use of microglial activation blockers could prevent this additional neuronal death.

}, issn = {1573-675X}, doi = {10.1007/s10495-015-1139-8}, author = {Tricarico, Paola Maura and Piscianz, Elisa and Monasta, Lorenzo and Kleiner, Giulio and Crovella, Sergio and Marcuzzi, Annalisa} } @article {7695, title = {Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17.}, journal = {Exp Ther Med}, volume = {9}, year = {2015}, month = {2015 Jun}, pages = {2047-2052}, abstract = {

Inflammatory bowel disease (IBD) is a chronic and progressive inflammatory condition of the gastrointestinal tract. Although the causative events that lead to the onset of IBD are yet to be fully elucidated, deregulation of immune and inflammatory mechanisms are hypothesized to significantly contribute to this disorder. Since the onset of IBD is often during infancy, in the present study, the serum values of a large panel of cytokines and chemokines in pediatric patients (<18 years; n=26) were compared with age-matched controls (n=37). While elevations in the serum level of several proinflammatory and immune regulating cytokines were confirmed, such as interleukin (IL)-1β, IL-5, IL-7, interferon (IFN)-γ-inducible protein-10, IL-16, cutaneous T-cell-attracting chemokine, leukemia inhibitory factor, monokine induced by γ-IFN, IFN-α2 and IFN-γ, notably decreased levels of IL-2, IL-17 and macrophage inhibitory protein-1β were also observed. Therefore, while a number of proinflammatory cytokines exhibit increased levels in IBD patients, pediatric IBD patients may also exhibit certain aspects of a reduced immunological response.

}, issn = {1792-0981}, doi = {10.3892/etm.2015.2370}, author = {Kleiner, Giulio and Zanin, Valentina and Monasta, Lorenzo and Crovella, Sergio and Caruso, Lorenzo and Milani, Daniela and Marcuzzi, Annalisa} } @article {8035, title = {To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies.}, journal = {Int J Mol Sci}, volume = {16}, year = {2015}, month = {2015}, pages = {21277-93}, abstract = {

Cytokines are the most important soluble mediators of inflammation. Rare pediatric diseases provided exemplar conditions to study the anti-inflammatory efficacy of new generation therapies (biologics/biopharmaceuticals) selectively targeting single cytokines. Monoclonal antibodies and recombinant proteins have revolutionized anti-inflammatory therapies in the last two decades, allowing the specific targeting of single cytokines. They are very effective in extinguishing inflammation from outside the cell, even with the risk of an excessive and prolonged immunosuppression. Small molecules can enter the cell and shutdown the valve of inflammation by directly targeting signal proteins involved in cytokine release or in response to cytokines. They are orally-administrable drugs whose dosage can be easily adjusted to obtain the desired anti-inflammatory effect. This could make these drugs more suitable for a wide range of diseases as stroke, gout, or neurological impairment, where inflammatory activation plays a pivotal role as trigger. Autoinflammatory diseases, which have previously put anti-cytokine proteins in the limelight, can again provide a valuable model to measure the real potential of small inhibitors as anti-inflammatory agents.

}, issn = {1422-0067}, doi = {10.3390/ijms160921277}, author = {Marcuzzi, Annalisa and Piscianz, Elisa and Valencic, Erica and Monasta, Lorenzo and Vecchi Brumatti, Liza and Tommasini, Alberto} } @article {8028, title = {Two-gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results.}, journal = {Mol Med Rep}, volume = {12}, year = {2015}, month = {2015 Oct}, pages = {6128-32}, abstract = {

Next-generation sequencing (NGS) has generated a large amount of sequence data with the requirement of frequent critical revisions of reported mutations. This innovative tool has proved to be effective in detecting pathogenic mutations; however, it requires a certain degree of experience to identify incidental findings. In the present study, whole exome sequencing analysis was performed for the molecular diagnosis and correct genotype/phenotype correlation between parents and a patient presenting with an atypical phenotype. In addition, mevalonic acid quantification and frequency analysis of detected variants in public databases and X-chromosome inactivation (XCI) studies on the patient{\textquoteright}s mother were performed. V377I as well as the S135L mutations were identified on the mevalonate kinase deficiency gene and the levels of mevalonic acid in the patient were 5,496 {\textmu}g/ml. A D59G variation, reported in ESP6500 in two healthy individuals, was found on the Martin Probst syndrome gene (RAB40AL). Based on XCI studies on the patient{\textquoteright}s mother, it is likely that RAB40AL escapes XCI, while still remaining balanced. In conclusion, the results of the present study indicated that the Martin Probst syndrome is an X-linked condition, which is probably not caused by RAB40AL mutations. Although NGS is a powerful tool to identify pathogenic mutations, the analysis of genetic data requires expert critical revision of all detected variants.

}, issn = {1791-3004}, doi = {10.3892/mmr.2015.4215}, author = {Bianco, Anna Monica and Faletra, Flavio and Vozzi, Diego and Girardelli, Martina and Knowles, Alessandra and Tommasini, Alberto and Zauli, Giorgio and Marcuzzi, Annalisa} } @article {3518, title = {Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds.}, journal = {Int J Mol Sci}, volume = {15}, year = {2014}, month = {2014}, pages = {6843-56}, abstract = {

Deregulation of the mevalonate pathway is known to be involved in a number of diseases that exhibit a systemic inflammatory phenotype and often neurological involvements, as seen in patients suffering from a rare disease called mevalonate kinase deficiency (MKD). One of the molecular mechanisms underlying this pathology could depend on the shortage of isoprenoid compounds and the subsequent mitochondrial damage, leading to oxidative stress and pro-inflammatory cytokines{\textquoteright} release. Moreover, it has been demonstrated that cellular death results from the balance between apoptosis and pyroptosis, both driven by mitochondrial damage and the molecular platform inflammasome. In order to rescue the deregulated pathway and decrease inflammatory markers, exogenous isoprenoid compounds were administered to a biochemical model of MKD obtained treating a murine monocytic cell line with a compound able to block the mevalonate pathway, plus an inflammatory stimulus. Our results show that isoprenoids acted in different ways, mainly increasing the expression of the evaluated markers [apoptosis, mitochondrial dysfunction, nucleotide-binding oligomerization-domain protein-like receptors 3 (NALP3), cytokines and nitric oxide (NO)]. Our findings confirm the hypothesis that inflammation is triggered, at least partially, by the shortage of isoprenoids. Moreover, although further studies are necessary, the achieved results suggest a possible role for exogenous isoprenoids in the treatment of MKD.

}, keywords = {Animals, Apoptosis, Carotenoids, Carrier Proteins, Cell Line, Cytokines, Diterpenes, Humans, Mevalonate Kinase Deficiency, Mevalonic Acid, Mice, Mitochondria, Nitric Oxide, Phytol, Terpenes}, issn = {1422-0067}, doi = {10.3390/ijms15046843}, author = {Tricarico, Paola Maura and Kleiner, Giulio and Valencic, Erica and Campisciano, Giuseppina and Girardelli, Martina and Crovella, Sergio and Knowles, Alessandra and Marcuzzi, Annalisa} } @article {3627, title = {Curcumin and inflammatory bowel disease: potential and limits of innovative treatments.}, journal = {Molecules}, volume = {19}, year = {2014}, month = {2014}, pages = {21127-53}, abstract = {

Curcumin belongs to the family of natural compounds collectively called curcuminoids and it possesses remarkable beneficial anti-oxidant, anti-inflammatory, anti-cancer, and neuroprotective properties. Moreover it is commonly assumed that curcumin has also been suggested as a remedy for digestive diseases such as inflammatory bowel diseases (IBD), a chronic immune disorder affecting the gastrointestinal tract and that can be divided in two major subgroups: Crohn{\textquoteright}s disease (CD) and Ulcerative Colitis (UC), depending mainly on the intestine tract affected by the inflammatory events. The chronic and intermittent nature of IBD imposes, where applicable, long-term treatments conducted in most of the cases combining different types of drugs. In more severe cases and where there has been no good response to the drugs, a surgery therapy is carried out. Currently, IBD-pharmacological treatments are generally not curative and often present serious side effects; for this reason, being known the relationship between nutrition and IBD, it is worthy of interesting the study and the development of new dietary strategy. The curcumin principal mechanism is the suppression of IBD inflammatory compounds (NF-κB) modulating immune response. This review summarizes literature data of curcumin as anti-inflammatory and anti-oxidant in IBD, trying to understand the different effects in CD e UC.

}, keywords = {Animals, Anti-Inflammatory Agents, Non-Steroidal, Chemistry, Pharmaceutical, Clinical Trials as Topic, Curcumin, Humans, Inflammatory Bowel Diseases, Molecular Targeted Therapy, Nanotechnology, Treatment Outcome}, issn = {1420-3049}, doi = {10.3390/molecules191221127}, author = {Vecchi Brumatti, Liza and Marcuzzi, Annalisa and Tricarico, Paola Maura and Zanin, Valentina and Girardelli, Martina and Bianco, Anna Monica} } @article {3505, title = {Mevalonate kinase deficiency and IBD: shared genetic background.}, journal = {Gut}, volume = {63}, year = {2014}, month = {2014 Aug}, pages = {1367-8}, keywords = {Genetic Predisposition to Disease, Humans, Inflammatory Bowel Diseases}, issn = {1468-3288}, doi = {10.1136/gutjnl-2013-306555}, author = {Bianco, Anna Monica and Girardelli, Martina and Vozzi, Diego and Crovella, Sergio and Kleiner, Giulio and Marcuzzi, Annalisa} } @article {1961, title = {Family history in early-onset inflammatory bowel disease.}, journal = {J Gastroenterol}, volume = {48}, year = {2013}, month = {2013 Jan}, pages = {144}, keywords = {Colitis, Ulcerative, Crohn Disease, Female, Humans, Male}, issn = {1435-5922}, doi = {10.1007/s00535-012-0654-4}, author = {Bianco, Anna Monica and Zanin, Valentina and Monasta, Lorenzo and Martelossi, Stefano and Marcuzzi, Annalisa and Crovella, Sergio} } @article {1904, title = {Clarification of the pleiotropic effects of statins on mevalonate pathway and the feedback regulation of isoprenoids requires more comprehensive investigation.}, journal = {Cell Biochem Funct}, volume = {30}, year = {2012}, month = {2012 Mar}, pages = {176}, keywords = {Carcinoma, Hepatocellular, Enzyme Inhibitors, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver Neoplasms, Simvastatin, Terpenes}, issn = {1099-0844}, doi = {10.1002/cbf.2798}, author = {Bianco, Anna Monica and Zanin, Valentina and Marcuzzi, Annalisa and Crovella, Sergio} } @article {1842, title = {Comments to the editor concerning the paper entitled "Preclinical renal cancer chemopreventive efficacy of geraniol by modulation of multiple molecular pathways" Shiekh Tanveer Ahmad et al.}, journal = {Toxicology}, volume = {293}, year = {2012}, month = {2012 Mar 11}, pages = {123-4}, keywords = {Animals, Antineoplastic Agents, Kidney Neoplasms, Male, Signal Transduction, Terpenes}, issn = {1879-3185}, doi = {10.1016/j.tox.2011.12.008}, author = {Vuch, Josef and Marcuzzi, Annalisa and Zanin, Valentina and Crovella, Sergio} } @article {1864, title = {A common genetic background could explain early-onset Crohn{\textquoteright}s disease.}, journal = {Med Hypotheses}, volume = {78}, year = {2012}, month = {2012 Apr}, pages = {520-2}, abstract = {

Crohn{\textquoteright}s disease (CD) is a multifactorial disease, in which environmental, microbial and genetic factors play important roles. CD is characterized by a chronic granulomatous inflammation by necrotic scarring with aspects of full-thickness wall. In spite of affecting mainly young adults, sometimes, CD can be present in the first year of life (early onset Crohn disease, EOCD) showing an unpredictable course and being often more severe than at older ages. In this paper we propose the hypothesis that EOCD patients should be analyzed using a Mendelian approach with family studies aimed to identify new loci directly involved in the early onset Crohn{\textquoteright}s disease. So we will leave the classic association study approach used until now for the identification of genes responsible for susceptibility to CD and propose linkage family analysis as alternative and powerful tool for the identification of new genetic variants associated with familiar cases of EOCD.

}, keywords = {Crohn Disease, Genetic Linkage, Genetic Predisposition to Disease, Humans, Models, Biological}, issn = {1532-2777}, doi = {10.1016/j.mehy.2012.01.023}, author = {Bianco, Anna Monica and Zanin, Valentina and Girardelli, Martina and Magnolato, Andrea and Martelossi, Stefano and Martellossi, Stefano and Tommasini, Alberto and Marcuzzi, Annalisa and Crovella, Sergio} } @article {1955, title = {The effect of clodronate on a mevalonate kinase deficiency cellular model.}, journal = {Inflamm Res}, volume = {61}, year = {2012}, month = {2012 Dec}, pages = {1363-7}, abstract = {

BACKGROUND: A potential anti-inflammatory effect of clodronate--an aminobisphosphonate--was described to antagonize the pro-inflammatory effects of the block in the mevalonate pathway, the main feature of a rare auto-inflammatory disease called mevalonate kinase deficiency (MKD).

OBJECTIVE: In this study we evaluated the potential anti-inflammatory effect of clodronate in MKD--a still orphan drug pediatric disease.

METHODS: We studied some biological parameters, nitric oxide production using Griess reagents and programmed cell death by flow cytometry, as common inflammatory parameters in MKD, in the presence of different doses of clodronate (1, 10 and 100 μM).

RESULTS: In our cellular model and in monocytes from patients with MKD, clodronate induced an increase in programed cell death and nitric oxide production in comparison with non-treated cells.

CONCLUSION: Our findings suggest that clodronate does not have an anti-inflammatory effect as previously reported but that it increases the epiphenomena of this pediatric disease.

}, keywords = {Adolescent, Adult, Alendronate, Animals, Anti-Inflammatory Agents, Apoptosis, Cell Line, Cells, Cultured, Child, Clodronic Acid, Female, Humans, Inflammation, Lipopolysaccharides, Male, Mevalonate Kinase Deficiency, Mice, Models, Biological, Monocytes, Nitric Oxide, Young Adult}, issn = {1420-908X}, doi = {10.1007/s00011-012-0537-4}, author = {Zanin, Valentina and Marcuzzi, Annalisa and Piscianz, Elisa and Vuch, Josef and Bianco, Anna Monica and Monasta, Lorenzo and Decorti, Giuliana and Crovella, Sergio} } @article {1844, title = {Inflammation profile of four early onset Crohn patients.}, journal = {Gene}, volume = {493}, year = {2012}, month = {2012 Feb 10}, pages = {282-5}, abstract = {

Crohn disease (CD) is a multifactorial disorder affecting mainly young adults. Sometimes, however, it can present in the first year of life (Early onset Crohn disease (EOCD)) showing an unpredictable course and can often be more severe than at older ages. Some cases have been associated to an underlying primary immunodeficiency such as IL10R deficiency. We studied the functional response to IL-10 and the genotype of IL-10 receptor in four patients with early onset crohn-like colitis. We found an IL10R variant, which may be associated with a decreased response to the cytokine in one patient. Further studies to determine its pathogenic effect should be performed. In addition IL-10 mediated inhibition of LPS-induced TNFα expression was measured in patient{\textquoteright}s monocytes.

}, keywords = {Crohn Disease, Cytokines, Humans, Inflammation, Monocytes, Nod2 Signaling Adaptor Protein, Polymorphism, Genetic, Receptors, Interleukin-10, Tumor Necrosis Factor-alpha}, issn = {1879-0038}, doi = {10.1016/j.gene.2011.11.043}, author = {Marcuzzi, Annalisa and Girardelli, Martina and Bianco, Anna Monica and Martelossi, Stefano and Magnolato, Andrea and Tommasini, Alberto and Crovella, Sergio} } @article {1943, title = {Lovastatin-induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line.}, journal = {Int J Dev Neurosci}, volume = {30}, year = {2012}, month = {2012 Oct}, pages = {451-6}, abstract = {

Mevalonic aciduria (MA), the most severe form of mevalonate kinase deficiency (MKD), is still an orphan drug disease and the pathogenetic mechanisms underlying neuronal dysfunction is still poorly understood. In our study we have investigated the apoptotic mechanism mediated by the exposure of the cultured neuroblastoma cell line, SH-SY5Y, to lovastatin in absence or in presence of the isoprenoid, geranylgeraniol, with the aim of unraveling the pathogenesis of MA. Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD. We demonstrate that apoptosis in neuronal lovastatin treated-cells is induced by the mitochondrial pathway, with caspase-9 as the initiator and caspase-3 as the effector caspase. The presence of geranylgeraniol modulates both the caspase-9 and caspase-3 activity in a dose-dependent way, confirming that this isoprenoid enters the mevalonate pathway, is metabolized and finally is able to by-pass the statin biochemical block reconstituting the mevalonate pathway. According to our findings, it should not be the time course adopted that modulates the apoptotic response but rather the isoprenoid itself. Being aware that our results have been obtained using a biochemical model of MKD, and not cells from patients with the disease, we believe our findings increase the knowledge of MA pathogenesis, and may possibly contribute to the development of novel therapeutic strategies.

}, keywords = {Analysis of Variance, Apoptosis, Caspases, Cell Line, Tumor, Diterpenes, Dose-Response Relationship, Drug, Drug Interactions, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lovastatin, Neuroblastoma, Time Factors}, issn = {1873-474X}, doi = {10.1016/j.ijdevneu.2012.06.002}, author = {Marcuzzi, Annalisa and Zanin, Valentina and Piscianz, Elisa and Tricarico, Paola Maura and Vuch, Josef and Girardelli, Martina and Monasta, Lorenzo and Bianco, Anna Monica and Crovella, Sergio} } @article {1928, title = {Mevalonate kinase deficiency: disclosing the role of mevalonate pathway modulation in inflammation.}, journal = {Curr Pharm Des}, volume = {18}, year = {2012}, month = {2012}, pages = {5746-52}, abstract = {

Inflammation is a highly regulated process involved both in the response to pathogens as well as in tissue homeostasis. In recent years, a complex network of proteins in charge of inflammation control has been revealed by the study of hereditary periodic fever syndromes. Most of these proteins belong to a few families and share the capability of sensing pathogen-associated and damageassociated molecular patterns. By interacting with each other, these proteins participate in the assembly of molecular platforms, called inflammasomes, which ultimately lead to the activation of cytokines, to the transcription of inflammatory genes or to the induction of cell apoptosis. Among hereditary periodic fever syndromes, mevalonate kinase deficiency (MKD) is the sole in which the phenotype did not directly associate with a deficiency of these proteins, but with a metabolic defect of the mevalonate pathway, highlighting the importance of this metabolic pathway in the inflammation control. Noteworthy, drugs acting on this pathway can greatly influence the inflammatory response. The modulation of inflammation by mevalonate pathway is of interest, since it may involve mechanisms not directly referable to inflammasomes. MKD provides a model to study these mechanisms and possibly to develop new classes of anti-inflammatory drugs.

}, keywords = {Animals, Anti-Inflammatory Agents, Apoptosis, Cytokines, Drug Design, Hereditary Autoinflammatory Diseases, Humans, Inflammasomes, Inflammation, Mevalonate Kinase Deficiency, Mevalonic Acid}, issn = {1873-4286}, author = {Marcuzzi, Annalisa and Crovella, Sergio and Monasta, Lorenzo and Vecchi Brumatti, Liza and Gattorno, Marco and Frenkel, Joost} } @article {1914, title = {Serum amyloid A and cholesterol: a pivotal role on inflammation.}, journal = {Amyloid}, volume = {19}, year = {2012}, month = {2012 Sep}, pages = {163-4; author reply 165-6}, keywords = {Animals, Humans, Serum Amyloid A Protein}, issn = {1744-2818}, doi = {10.3109/13506129.2012.689266}, author = {Tricarico, Paola Maura and Marcuzzi, Annalisa and Zanin, Valentina and Kleiner, Giulio and Bianco, Anna Monica and Crovella, Sergio} } @article {1909, title = {Specific protein profile in cerebrospinal fluid from HIV-1-positive cART-treated patients affected by neurological disorders.}, journal = {J Neurovirol}, volume = {18}, year = {2012}, month = {2012 Oct}, pages = {416-22}, abstract = {

Cytokines/chemokines are involved in the immune response of infections, including HIV-1. We defined the profile of 48 cytokines/chemokines in cerebrospinal fluid from 18 cART patients with chronic HIV-1 infection by Luminex technology. Nine patients were affected with leukoencephalopathies: five with John Cunningham virus (JCV) + progressive multifocal leukoencephalopathy (PML) and four with JCV-not determined leukoencephalopathy (NDLE). In addition, nine HIV-1-positive patients with no neurological signs (NND) and five HIV-1-negative patients affected with acute disseminated encephalomyelitis (ADEM) were enrolled. Ten cytokines (IL-15, IL-3, IL-16, IL-18, CTACK, GRO1, SCF, MCP-1, MIF, SDF) were highly expressed in HIV-1-positive patients while IL-1Ra and IL-17 were present at a lower level. In addition, the levels of IL-17, IL-9, FGF-basic, MIP-1β, and MCP-1 were significantly higher (p < 0.05) in patients with neurological diseases (PML, NDLE, ADEM) with respect to NND. Focusing the attention to the cytokine profile in JCV + PML patients with respect to JCV-NDLE patients, only TNF-β was significantly downregulated (p < 0.05) in JCV + PML patients. This pilot study emphasized the role of immunoregulation in HIV-1-related neurological disorders during cART treatment.

}, keywords = {Adult, Aged, Anti-HIV Agents, Cytokines, Encephalomyelitis, Acute Disseminated, Female, HIV Infections, HIV-1, Humans, Leukoencephalopathy, Progressive Multifocal, Male, Middle Aged, Pilot Projects}, issn = {1538-2443}, doi = {10.1007/s13365-012-0109-y}, author = {Zanin, Valentina and Delbue, Serena and Marcuzzi, Annalisa and Tavazzi, Eleonora and Del Savio, Rossella and Crovella, Sergio and Marchioni, Enrico and Ferrante, Pasquale and Comar, Manola} } @article {1939, title = {TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide.}, journal = {Cytokine}, volume = {60}, year = {2012}, month = {2012 Oct}, pages = {43-6}, abstract = {

The potent inducer of apoptosis TRAIL/Apo2 ligand is now under considerations in clinical trials for the treatment of different types of cancer. Since the natural history of cancer is often characterized by microbial infections, we have investigated the effect of recombinant human TRAIL in a mouse model of systemic acute inflammation of microbial origin represented by BALB/c mice treated with either bacterial muramyldipeptide (MDP) or lipopolysaccharide (LPS). When administered intraperitoneally (i.p.), these inflammatory bacterial compounds triggered a severe systemic inflammatory response within 2h, represented by body temperature elevation, increase of circulating serum amyloid-A (SAA) and of the number of leukocytes in the peritoneal cavity. Moreover, both MDP and LPS induced a significant elevation of the circulating levels of several inflammatory cytokines and chemokines. Noteworthy, pre-treatment with recombinant human TRAIL 48 and 72 h before administration of either MDP or LPS, significantly counteracted all acute inflammatory responses, including the elevation of key pro-inflammatory cytokines/chemokines such as IL-1α, IL-6, G-CSF, MCP-1. These data demonstrate for the first time that TRAIL has a potent anti-inflammatory activity, which might be beneficial for the anti-tumoral activity of TRAIL.

}, keywords = {Acetylmuramyl-Alanyl-Isoglutamine, Acute Disease, Animals, Chemokine CCL2, Cytokines, Disease Models, Animal, Down-Regulation, Granulocyte Colony-Stimulating Factor, Humans, Immunoassay, Inflammation, Inflammation Mediators, Interleukin-1alpha, Interleukin-6, Lipopolysaccharides, Male, Mice, Mice, Inbred BALB C, Recombinant Proteins, Serum Amyloid A Protein, TNF-Related Apoptosis-Inducing Ligand}, issn = {1096-0023}, doi = {10.1016/j.cyto.2012.06.001}, author = {Marcuzzi, Annalisa and Secchiero, Paola and Crovella, Sergio and Zauli, Giorgio} } @article {1600, title = {Comments on {\textquoteright}{\textquoteright}Geranylgeraniol--a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw" by Ziebart T et al. (2011).}, journal = {Oral Oncol}, volume = {47}, year = {2011}, month = {2011 May}, pages = {436-7; author reply 438}, keywords = {Bone Density Conservation Agents, Diphosphonates, Diterpenes, Humans, Jaw Diseases, Osteonecrosis}, issn = {1879-0593}, doi = {10.1016/j.oraloncology.2011.02.017}, author = {Marcuzzi, Annalisa and Zanin, Valentina and Crovella, Sergio and Pontillo, Alessandra} } @article {1725, title = {The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.}, journal = {Pediatr Res}, volume = {70}, year = {2011}, month = {2011 Jul}, pages = {78-82}, abstract = {

The shortage of geranylgeranyl-pyrophosphate (GGPP) was associated to an increased IL-1β release in the autoinflammatory syndrome mevalonate kinase deficiency (MKD), a rare inherited disease that has no specific therapy. Farnesyltransferase inhibitors (FTIs) act at the end of mevalonate pathway. Two FTIs, tipifarnib (Tip) and lonafarnib (Lon), were therefore evaluated as possible therapeutical choices for the treatment of MKD. FTIs could lead to a redirection of the limited available number of mevalonate intermediates preferentially to GGPP synthesis, eventually preventing the uncontrolled inflammatory response. The effect of Tip and Lon on intracellular cholesterol level (ICL) and on proinflammatory cytokines secretion was evaluated in a cellular model of MKD, chemically obtained treating RAW 264.7 cells with lovastatin (Lova) and alendronate (Ald). The combination of FTIs with the isoprenoid geraniol (GOH) was also tested both in this model and in monocytes isolated from MKD patients. Tip and Lon proved to revert the ICL lowering and to significantly reduce the lipopolysaccharide-induced cytokines secretion in Ald-Lova -RAW 264.7 cells. This anti-inflammatory effect was amplified combining the use of GOH with FTIs. The effect of GOH and Tip was successfully replicated in MKD patients{\textquoteright} monocytes. Tip and Lon showed a dramatic anti-inflammatory effect in monocytes where mevalonate pathway was chemically or genetically impaired.

}, keywords = {Alendronate, Animals, Anti-Inflammatory Agents, Cell Line, Child, Child, Preschool, Cholesterol, Cytokines, Dose-Response Relationship, Drug, Enzyme Inhibitors, Farnesyltranstransferase, Humans, Inflammation Mediators, Lovastatin, Male, Mevalonate Kinase Deficiency, Mice, Monocytes, Phosphotransferases (Alcohol Group Acceptor), Piperidines, Polyenes, Polyisoprenyl Phosphates, Polyunsaturated Alkamides, Pyridines, Quinolones, Terpenes}, issn = {1530-0447}, doi = {10.1038/pr.2011.303}, author = {Marcuzzi, Annalisa and De Leo, Luigina and Decorti, Giuliana and Crovella, Sergio and Tommasini, Alberto and Pontillo, Alessandra} } @article {1672, title = {Geraniol rescues inflammation in cellular and animal models of mevalonate kinase deficiency.}, journal = {In Vivo}, volume = {25}, year = {2011}, month = {2011 Jan-Feb}, pages = {87-92}, abstract = {

BACKGROUND/AIM: The inhibition of the mevalonate pathway through genetic defects such as mevalonate kinase deficiency (MKD) or pharmacological drugs such as aminobisphosphonates causes a shortage of intermediate compounds, in particular geranylgeranyl-pyrophosphate (GGPP), which is associated with the consequent augmented IL-1β release in monocytes. Considering that, due to its biochemical structure, isoprenoid geraniol enters the mevalonate pathway and may revert the genetic or pharmacological inhibition, the present study tested isoprenoid geraniol in cellular and animal MKD models obtained through the use of aminobisphosphonate pamidronate.

MATERIALS AND METHODS: The effect of natural isoprenoid geraniol on bacterial induced-inflammation was evaluated in a monocytic cell line (Raw 264.7) and in Balb/c mice treated with pamidronate.

RESULTS: Geraniol diminished the levels of inflammatory markers induced by pamidronate stimuli in vitro and in vivo.

CONCLUSION: Geraniol may be proposed as a novel therapeutic approach for the orphan disease MKD, and may also be considered for the evaluation of possible inflammatory side-effects of aminobisphosphonates.

}, keywords = {Animals, Anti-Inflammatory Agents, Cell Line, Diphosphonates, Disease Models, Animal, Inflammation, Lipopolysaccharides, Mevalonate Kinase Deficiency, Mice, Mice, Inbred BALB C, Monocytes, Nitric Oxide, Terpenes}, issn = {1791-7549}, author = {Marcuzzi, Annalisa and Crovella, Sergio and Pontillo, Alessandra} } @article {1761, title = {Letter to the editor: acute effects of intravenous administration of pamidronate in patients with osteoporosis.}, journal = {J Korean Med Sci}, volume = {26}, year = {2011}, month = {2011 Jun}, pages = {848-9; author reply 850}, keywords = {Anti-Inflammatory Agents, Cytokines, Diphosphonates, Humans, Injections, Intravenous, Osteoporosis}, issn = {1598-6357}, doi = {10.3346/jkms.2011.26.6.848}, author = {Marcuzzi, Annalisa and Zanin, Valentina and Vuch, Josef and Pontillo, Alessandra and Crovella, Sergio} } @article {1673, title = {Decreased cholesterol levels reflect a consumption of anti-inflammatory isoprenoids associated with an impaired control of inflammation in a mouse model of mevalonate kinase deficiency.}, journal = {Inflamm Res}, volume = {59}, year = {2010}, month = {2010 May}, pages = {335-8}, abstract = {

OBJECTIVE: The aim of this study was to evaluate, in a mouse model of mevalonate kinase deficiency (MKD), the possible link between inflammatory symptoms and serum cholesterol levels.

MATERIALS AND METHODS: Balb/c mice were treated with alendronate and bacterial muramyl dipeptide. Body temperature, interleukin-1 beta (IL-1 beta) secretion and serum cholesterol levels were measured.

RESULTS: An increased production of the pro-inflammatory cytokine IL-1 beta (p < 0.05) and a rise in body temperature (p < 0.05) was observed, while, in parallel, serum cholesterol concentration significantly decreased (p < 0.05). These effects were completely reversed when animals were treated with exogenous isoprenoids.

CONCLUSIONS: In the mouse model of MKD, the inflammatory response is associated with a reduction in cholesterol levels, and hence this parameter could be used as an indicator of isoprenoid consumption. In addition, plant derived isoprenoids could represent candidate treatments for this disease.

}, keywords = {Animals, Anti-Inflammatory Agents, Cholesterol, Disease Models, Animal, Inflammation, Interleukin-1beta, Male, Mevalonate Kinase Deficiency, Mice, Mice, Inbred BALB C, Random Allocation, Terpenes}, issn = {1420-908X}, doi = {10.1007/s00011-010-0168-6}, author = {Marcuzzi, Annalisa and Decorti, Giuliana and Pontillo, Alessandra and Ventura, Alessandro and Tommasini, Alberto} } @article {1674, title = {Natural isoprenoids inhibit LPS-induced-production of cytokines and nitric oxide in aminobisphosphonate-treated monocytes.}, journal = {Int Immunopharmacol}, volume = {10}, year = {2010}, month = {2010 Jun}, pages = {639-42}, abstract = {

The inhibition of mevalonate pathway through genetic defects (mevalonate kinase deficiency, MKD) or pharmacologic drugs (aminobisphosphonates) causes a shortage of intermediate compounds and, in particular, of geranylgeranyl-pyrophosphate (GGPP) associated to the activation of caspase-1 and IL-1beta release. Geraniol (GOH), farnesol (FOH), geranylgeraniol (GGOH) and menthol (MOH), due to their isoprenoid structure, are supposed to enter the mevalonate pathway and to by-pass the biochemical block, reconstituting the pathway. Considering the already known side effects of aminobisphosphonates, and the lack of a specific treatment for MKD, we evaluated the impact of these natural isoprenoids compounds in a RAW cell lines chemically treated with the aminobisphosphonate alendronate, and in monocytes isolated from 2 patients affected by MKD. GOH, FOH, GGOH and MOH were all capable to diminish inflammatory marker levels induced by LPS. These natural isoprenoids could be proposed as novel therapeutic approach for the still orphan drug MKD, but also considered for the evaluation of possible inflammatory side effects of aminobisphosphonates.

}, keywords = {Animals, Cell Line, Cells, Cultured, Child, Child, Preschool, Cytokines, Diphosphonates, Humans, Inflammation, Interleukin-1beta, Lipopolysaccharides, Male, Mevalonate Kinase Deficiency, Mice, Monocytes, Nitric Oxide, Terpenes}, issn = {1878-1705}, doi = {10.1016/j.intimp.2010.03.008}, author = {Marcuzzi, Annalisa and Tommasini, Alberto and Crovella, Sergio and Pontillo, Alessandra} } @article {1654, title = {Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: in vitro and in vivo approaches.}, journal = {Pharmacol Res}, volume = {61}, year = {2010}, month = {2010 Jun}, pages = {506-10}, abstract = {

Mevalonate kinase deficiency (MKD) is a rare inborn auto-inflammatory disease due to the impairment of the pathway for the biosynthesis of cholesterol and non-sterol isoprenoids. The shortage of isoprenoids compounds and in particular of geranylgeranylpyrophosphate (GGPP) was recently associated to the MKD characteristic inflammatory attacks. The aim of this study is to demonstrate that the normalization of the mevalonate pathway intermediates levels and in particular of GGPP, through the specific inhibition of farnesyl-transferase (FT) with Manumycin A could ameliorate the inflammatory phenotype of MKD patients. The effect of Manumycin A was first evaluated in MKD mouse and cellular models, chemically obtained using the aminobisphosphonate alendronate (ALD), and then in monocytes isolated from 2 MKD patients. Our findings were compared to those obtained by using natural exogenous isoprenoids (NEIs). Manumycin A was able to significantly reduce the inflammatory marker serum amyloid A in ALD-treated Balb/c mice, as well as IL-1 beta secretion in ALD-monocytes and in MKD patients. These results clearly showed that, through the inhibition of FT, an increased number of mevalonate pathway intermediates could be redirected towards the synthesis of GGPP diminishing the inflammatory response. The importance in limiting the shortage of GGPP was emphasized by the anti-inflammatory effect of NEIs that, due to their biochemical structure, can enter the MKD pathway. In conclusion, manumycin A, as well as NEIs, showed anti-inflammatory effect in MKD models and especially in MKD-monocytes, suggesting novel approaches in the treatment of MKD, an orphan disease without any efficacious treatment currently available.

}, keywords = {Adult, Animals, Anti-Inflammatory Agents, Cells, Cultured, Child, Preschool, Enzyme Inhibitors, Farnesyltranstransferase, Female, Humans, Male, Mevalonate Kinase Deficiency, Mevalonic Acid, Mice, Mice, Inbred BALB C, Monocytes, Polyenes, Polyisoprenyl Phosphates, Polyunsaturated Alkamides, Young Adult}, issn = {1096-1186}, doi = {10.1016/j.phrs.2010.02.012}, author = {De Leo, Luigina and Marcuzzi, Annalisa and Decorti, Giuliana and Tommasini, Alberto and Crovella, Sergio and Pontillo, Alessandra} }